Grifols 将来の成長

Future 基準チェック /36

Grifols利益と収益がそれぞれ年間28.2%と6.1%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に9.5% 30.9%なると予測されています。

主要情報

28.2%

収益成長率

30.9%

EPS成長率

Biotechs 収益成長	0%
収益成長率	6.1%
将来の株主資本利益率	9.5%
アナリストカバレッジ	Good
最終更新日	07 Aug 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

BMV:GRFP N - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	8,125	765	902	1,133	12
12/31/2025	7,606	623	662	907	16
12/31/2024	7,071	407	386	629	14
6/30/2024	6,811	166	77	377	N/A
3/31/2024	6,656	189	-187	105	N/A
12/31/2023	6,592	59	-87	208	N/A
9/30/2023	6,535	23	-217	119	N/A
6/30/2023	6,479	-5	-496	-123	N/A
3/31/2023	6,358	47	-485	-107	N/A
12/31/2022	6,064	208	-386	-11	N/A
9/30/2022	5,549	149	-272	50	N/A
6/30/2022	5,207	66	-36	289	N/A
3/31/2022	5,016	112	137	454	N/A
12/31/2021	4,933	189	282	597	N/A
9/30/2021	5,044	361	400	727	N/A
6/30/2021	5,199	667	597	909	N/A
3/31/2021	5,231	562	847	1,183	N/A
12/31/2020	5,340	619	748	1,110	N/A
9/30/2020	5,392	687	663	1,081	N/A
6/30/2020	5,353	557	551	964	N/A
3/31/2020	5,235	697	425	842	N/A
12/31/2019	5,099	625	157	569	N/A
9/30/2019	4,961	552	309	668	N/A
6/30/2019	4,790	565	275	634	N/A
3/31/2019	4,620	568	147	477	N/A
12/31/2018	4,487	597	430	737	N/A
9/30/2018	4,332	699	365	680	N/A
6/30/2018	4,246	704	405	712	N/A
3/31/2018	4,279	672	N/A	789	N/A
12/31/2017	4,318	663	N/A	842	N/A
9/30/2017	4,348	571	N/A	751	N/A
6/30/2017	4,291	559	N/A	765	N/A
3/31/2017	4,153	554	N/A	640	N/A
12/31/2016	4,050	545	N/A	553	N/A
9/30/2016	4,014	537	N/A	683	N/A
6/30/2016	3,986	535	N/A	652	N/A
3/31/2016	3,985	529	N/A	767	N/A
12/31/2015	3,935	532	N/A	743	N/A
9/30/2015	3,789	533	N/A	755	N/A
6/30/2015	3,645	507	N/A	836	N/A
3/31/2015	3,466	478	N/A	888	N/A
12/31/2014	3,355	470	N/A	979	N/A
9/30/2014	3,133	417	N/A	882	N/A
6/30/2014	2,972	388	N/A	712	N/A
3/31/2014	2,856	376	N/A	625	N/A
12/31/2013	2,742	346	N/A	592	N/A
9/30/2013	2,708	326	N/A	525	N/A

アナリストによる今後の成長予測

収入対貯蓄率: GRFP Nの予測収益成長率 (年間28.2% ) は貯蓄率 ( 7.9% ) を上回っています。

収益対市場: GRFP Nの収益 ( 28.2% ) はMX市場 ( 11.3% ) よりも速いペースで成長すると予測されています。

高成長収益: GRFP Nの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: GRFP Nの収益 ( 6.1% ) MX市場 ( 7.1% ) よりも低い成長が予測されています。

高い収益成長: GRFP Nの収益 ( 6.1% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: GRFP Nの自己資本利益率は、3年後には低くなると予測されています ( 9.5 %)。

Grifols 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Grifols, S.A. Reaffirms Earnings Guidance for the Full Year 2024

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Recent updates

Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

Grifols Receives Fda Approval to Treat Surgical Bleeding in Pediatric Patients with Its Fibrin Sealant Solution

Brookfield Reportedly Courts Sovereign Funds to Join Grifols Takeover Bid

Grifols, S.A. Reaffirms Earnings Guidance for the Full Year 2024

Grifols Receives Expanded XEMBIFY (Immune Globulin Subcutaneous Human-Klhw) Label in U.S., Strengthening Its Ig Portfolio for Patients

Grifols Family Holders, Brookfield to Evaluate Possible Joint Takeover Bid

Haiyingkang (Qingdao) Medical Technology Co., Ltd. completed the acquisition of 20% equity stake in Shanghai RAAS Blood Products Co., Ltd. (SZSE:002252) from Grifols, S.A. (BME:GRF).

Grifols, S.A. to Report Q2, 2024 Results on Jul 30, 2024

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Grifols Announces Executive Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Reportedly in Talks to Sell Raas Stake to China Resources

Grifols, S.A. to Report Q3, 2023 Results on Nov 02, 2023

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Grifols Launches Alphaid™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic Copd

Grifols, S.A. to Report Fiscal Year 2022 Results on Feb 28, 2023

Grifols, S.A. to Report Q3, 2022 Results on Nov 08, 2022

Grifols Receives FDA Clearance for AlphaID(TM) At Home, the First Free Service for U.S. Consumers to Determine Their Risk for Alpha-1

Grifols Announces Management Changes

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Grifols, S.A. to Report First Half, 2022 Results on Jul 28, 2022

Grifols, S.A., Annual General Meeting, Jun 09, 2022

Grifols, S.A. (BME:GRF) completed the acquisition of a 45.48% stake in Biotest Aktiengesellschaft (XTRA : BIO3) from Tiancheng International Investment Limited.

Grifols, S.A. (BME:GRF) acquired Grifols Escrow Issuer, S.A.U. for $0.06 million.

Grifols to Provide Korean Red Cross with Procleix Panther for Blood Screening, Extending Donor Testing Leadership in Asia

Grifols, S.A. Declares Ordinary Dividend for the Fiscal Year Ended December 31, 2020, Payable on June 7, 2021

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘